MedPath

FDA Expands Indications for Cerapedics' i-FACTOR Bone Graft in Cervical Spinal Fusion

• The FDA has approved expanded indications for Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft, enhancing its utility in spinal fusion procedures. • i-FACTOR is now approved for single-level ACDF with an allograft bone ring or with PEEK or titanium interbody devices, alongside anterior plate fixation. • This expansion underscores Cerapedics' commitment to evidence-based bone grafting, providing surgeons with a proven and safe option for spinal fusion. • Backed by Level 1 clinical data, i-FACTOR is the only spinal bone graft powered by P-15 Osteogenic Cell Binding Peptide, ensuring a precise bone-building mechanism.

Cerapedics Inc. announced FDA approval for expanded indications for its i-FACTOR P-15 Peptide Enhanced Bone Graft, a significant advancement in bone grafting solutions for spinal fusion. The approval allows i-FACTOR to be used in single-level anterior cervical discectomy fusion (ACDF) with an allograft bone ring, or in conjunction with a PEEK, titanium alloy, or PEEK/titanium fusion interbody device cleared by the FDA for use in the cervical spine, and with supplemental anterior plate fixation.
This expansion broadens the applicability of i-FACTOR, a Class III FDA-approved bone graft, which has been available in the U.S. since 2015. The approval is based on a premarket approval (PMA) investigational device exemption (IDE) study, reflecting Cerapedics' dedication to investing in evidence that supports clinical practice.

Clinical Significance

Anterior cervical discectomy fusion (ACDF) is a surgical procedure performed to alleviate pain resulting from conditions such as degenerative disc disease. The procedure involves removing a damaged disc and fusing the adjacent vertebral bones to stabilize the spine and decompress the spinal cord. Bone grafts are essential for achieving fusion, facilitating bone growth between the vertebrae over time.
In 2023, approximately 465,000 spinal fusion cases in the U.S. utilized a bone graft replacement, highlighting the importance of effective bone grafting solutions. The expanded indications for i-FACTOR provide surgeons with a clinically proven option backed by Level 1 human clinical data published in Spine and Neurosurgery.

i-FACTOR P-15 Peptide Enhanced Bone Graft

i-FACTOR is powered by P-15 Osteogenic Cell Binding Peptide, which offers a precise bone-building mechanism. It is indicated for skeletally mature patients requiring reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7. The bone graft has a demonstrated safety profile, comparable to local autograft in single-level ACDF, with statistical superiority in overall success at one and two years.
Valeska Schroeder, CEO of Cerapedics, stated, "This label expansion approval is part of our deep commitment to bring scientific rigor to bone grafting so surgeons and the patients they treat have access to products with proven safety, efficacy and evidence. We are proud to have FDA approval for the safe and effective use of i-FACTOR in PEEK and titanium cages."

Cerapedics' Commitment

Cerapedics aims to redefine the standard of care for bone repair, focusing on faster and higher rates of bone healing without compromising safety. The company's products are used in over four million spine, orthopedics, trauma, and interventional procedures annually worldwide.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ventris Medical's Backpack Receives FDA 510(k) Clearance for Orthopedic and Spinal Fusion Procedures

Ventris Medical's Backpack, a porous biologic scaffold, has received FDA 510(k) clearance for orthopedic and spinal fusion applications, enhancing bone formation and cell proliferation.
Backpack AF utilizes a collagen mesh pouch prefilled with osteoinductive Allocell AF allograft fibers, promoting bone remodeling through a 100% biologic graft system.

RevBio's Tetranite Bone Adhesive Trial Expanded Following FDA Nod, Gains CMS Reimbursement

RevBio received FDA approval to expand its clinical trial for Tetranite, a bone adhesive biomaterial, after demonstrating safety in initial patients.
The trial expansion allows Tetranite's use in intradural cases like tumor resection, beyond its initial extradural cranial flap fixation application.

Theradaptive's OsteoAdapt SP Spinal Fusion Trial Expands to ALIF and LLIF Procedures

Theradaptive's OsteoAdapt SP clinical trial expands to include anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) procedures, alongside the existing transforaminal interbody fusion (TLIF) approach.
The FDA approved expansion triples the number of investigational sites in the U.S., facilitating broader patient access to the study of this novel therapy for degenerative disc disease.

FDA Clears Foundation Surgical's Vertiwedge® Intraosseous System for Vertebral Body Replacement

The FDA has granted 510(k) clearance to Foundation Surgical's Vertiwedge® Intraosseous System, a novel device for partial vertebral body replacement in the thoracolumbar spine.
Indicated for use in T1-L5, the device addresses conditions like trauma, fractures, tumors, and degenerative spine disease by restoring vertebral height.

Acuitive Technologies' Citrepore Receives FDA Clearance for Bone Void Filling

Acuitive Technologies has received FDA 510(k) clearance for Citrepore, a synthetic bioactive bone void filler designed for orthopedic applications.
Citrepore's unique composition promotes natural bone healing by leveraging citrate, a key component in bone metabolism and formation.

NovaBone Putty Receives FDA Clearance for Interbody Fusion Applications

NovaBone Putty has received FDA clearance for use in interbody fusion procedures, expanding its application in spinal and orthopedic surgeries.
The bioactive synthetic bone graft is formulated with Calcium Sodium Phosphosilicate (Bioglass) to facilitate bone void filling and natural bone regeneration.

Acuitive Technologies' CITREPORE Receives FDA Clearance as Novel Bone Void Filler

Acuitive Technologies secured FDA 510(k) clearance for CITREPORE, a synthetic bioactive bone void filler utilizing CITREGEN® technology, designed for orthopedic procedures.
CITREPORE is engineered to resorb predictably, facilitating bone regeneration by releasing citrate, which enhances bone metabolism and formation during the healing process.

L&K Biomed's BluEX Lumbar Expandable Cage System Receives FDA Approval

L&K Biomed secured FDA 510(k) clearance for its BluEX Lumbar Expandable Cage System, designed for enhanced bone integration and versatile surgical approaches.
The BluEX system features six cage designs adaptable for anterior, posterior, lateral, ATP, and endoscopic lumbar approaches, offering surgeons greater flexibility.

SpineGuard's PsiFGuard Receives FDA Clearance for Sacroiliac Joint Fusion

SpineGuard's PsiFGuard, a smart drilling device for posterior sacroiliac fusion (PsiF), has received FDA 510(k) clearance for commercial use in the United States.
The PsiFGuard device utilizes SpineGuard's Dynamic Surgical Guidance (DSG®) technology to enhance the accuracy of implant placement in SI joint fusion procedures.

Vy Spine and Nvision Gain FDA Clearance for 3D-Printed Spinal Implants

Vy Spine received FDA clearance for its LumiVy OsteoVy PEKK Lumbar IBF device, utilizing 3D-printed OXPEKK material for enhanced osseointegration.
Nvision Biomedical Technologies secured FDA clearance for its 3D-printed PEEK Interbody System, incorporating porous structures for bone ingrowth.

Reference News

[1]
FDA Expands Indications for iFactor Use in Spine Surgery | Orthopedics This Week
ryortho.com · Oct 19, 2024

FDA expands Cerapedics Inc.'s iFactor bone graft labeling for single-level anterior cervical discectomy fusion (ACDF) wi...

[2]
Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice ... - Ortho Spine News
orthospinenews.com · Sep 24, 2024

Cerapedics Inc. announces FDA approval for expanded use of i-FACTOR P-15 Peptide Enhanced Bone Graft in single-level ant...

[3]
Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in ... - PR Newswire
prnewswire.com · Sep 24, 2024

Cerapedics announces FDA approval for expanded use of i-FACTOR P-15 Peptide Enhanced Bone Graft in single-level anterior...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy